Tamar Elkeles, a director of PetMed Express, Inc., filed a statement of changes in beneficial ownership on September 21, 2026, reporting the acquisition of 49,923 shares of common stock on September 17, 2026.

Key Highlights

  • Reporting Person: Tamar Elkeles, identified as a Director of PetMed Express, Inc.
  • Shares Acquired: 49,923 shares of common stock acquired on September 17, 2026, at a price of $0.
  • Award Type: A restricted stock award granted under the PetMed Express, Inc. 2024 Omnibus Incentive Plan.
  • Vesting Schedule: The award will vest in its entirety on September 17, 2027, subject to continued service on the Board of Directors.
  • Resulting Ownership: Following the transaction, Elkeles directly holds 49,923 shares of common stock.

Director Equity Grant Details for PetMed Express

According to the filing, Tamar Elkeles, a director of PetMed Express, Inc. (NASDAQ:PETS), an online pet pharmacy and direct-to-consumer retailer of prescription and non-prescription pet medications, received a restricted stock award on September 17, 2026. The transaction was coded "A," indicating an acquisition, and the shares were obtained at a price of $0, consistent with a compensatory equity grant rather than an open-market purchase.

The filing discloses that the award consists of 49,923 shares of common stock made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan. The restricted shares "will vest in its entirety on September 17, 2027, subject to continued service on the Board of Directors," according to the explanation of responses included in the filing. Following the reported transaction, Elkeles beneficially owns 49,923 shares directly, with no derivative securities reported in Table II of the filing.

The filing was submitted on September 21, 2026, by Elkeles individually, as indicated by the "Form filed by One Reporting Person" selection. The filing does not reflect any amendment to a prior submission, and no deemed execution date was recorded for the transaction. No indirect ownership or derivative securities positions were reported.

What Was Disclosed

PetMed Express director Tamar Elkeles reported the receipt of 49,923 restricted shares of common stock on September 17, 2026, at no cost, under the company's 2024 Omnibus Incentive Plan. The shares are scheduled to vest on September 17, 2027, contingent on continued board service.